Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Smart Growth Strategy: More Room At White Oak, Less In Budget

Executive Summary

Master plan update will study adding 3,800 more employees to White Oak headquarters or elsewhere in area.

You may also be interested in...



FDA Posts OCI Agent In Singapore, But Other Foreign Offices Close

China offices consolidate to allow FDA to 'strategically focus its resources.'

FDA’s Rent Is Too Damn High: Consolidated Labs Cost More Than Off-Campus Space

After moving thousands of employees from leased off-campus space to the new Life Sciences-Biodefense Laboratory at its White Oak headquarters, FDA is paying 23% more in rent.

FDA Field Operations Would Endure Reductions Under Budget

President Obama’s FY 2016 blueprint includes cuts to ‘low-priority’ enforcement, surveillance and other activities in FDA human drugs and biologics programs, but still increases those operations overall.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS057498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel